Company Of The Day: Pfizer

+13.89%
Upside
49.71
Market
56.62
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus last year.

Why?

Relevant Articles
  1. Should You Buy Pfizer Stock Ahead of Its Q3 Results?
  2. Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick
  3. Should You Buy Pfizer Stock After An Upbeat Q2?
  4. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  5. Should You Buy, Sell, Or Hold Pfizer Stock At $52?
  6. Here’s A Better Pick Over FedEx Stock

While sales were weighed down by lower Covid-19 vaccine sales, this was partly offset by strong sales of Pfizer’s antiviral drug Paxlovid as well as Prevnar and Eliquis.

So What?

PFE stock was up by about 3% in Tuesday’s trading.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Returns Nov 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 3% -19% 48%
 S&P 500 Return 0% -19% 72%
 Trefis Multi-Strategy Portfolio 0% -22% 208%

[1] Month-to-date and year-to-date as of 11/2/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates